• MR System

    Image Guided Thermal Therapy

    The BSD-2000 3D/MR employs the next generation of non-invasive thermometry.
    MR images are translated to map and visualize temperature, allowing
    for precision placement of the hyperthermic heating zone.
    Not for sale in the United States.
  • BSD-200 3D/MR Open Applicator

    Increase Workflow with
    easier patient access

    The Sigma Eye/MR applicator's side opening allows for more natural
    patient access. The unit can be removed and stored, allowing
    the MR system to be used for traditional imaging.
    Not for sale in the United States.
  • BSD-2000 3D/MR Dr with Patient

    Temperature Imaging during treatment

    There is no interruption during the hyperthermia/imaging process. The patient remains in the
    MR system during the full course of treatment. A water bolus is used to make connection
    between the RF signal and the patient. Circulated water can be cooled or heated for patient comfort.
    Not for sale in the United States.
  • BSD-2000 3D/MR Operator

    Realtime Heat Zone Steering

    A great benefit of image-guided thermal therapy
    is the ability to validate and electronically steer the heat zone to
    ensure proper treatment placement and target temperature.
    Not for sale in the United States.

Who is Pyrexar Medical

By leveraging the therapeutic power of focused heat, Pyrexar Medical seeks to revolutionize cancer care. We aim to enhance traditional cancer therapies, with clinically proven and effective options.

We are committed to continuing to advance these pioneering solutions, as we strive to redefine the landscape of cancer care for a brighter and healthier future.

Pyrexar Medical Quality Certifications

Clinical Evidence Matters

Randomized clinical trials (RCT’s) have show significant improvement in clinical outcomes when hyperthermia was added to radiotherapy and/or chemotherapy. Experts in clinical hyperthermia held a consensus meeting (Kadota Fund International Forum 2004) about the evidence of the published clinical results of the RCT’s. Level 1 evidence was found for bladder cancer, breast cancer, cervical cancer, cancer of the esophagus, lymph nodes of head and neck tumors, rectum cancer, soft tissue sarcoma, malignant melanoma, glioblastoma multiform, and various superficial cancers.

Hyperthermia chart demonstrating proven clinical results
Cancer Immune Modulaton

Heat Matters

According to the standards set by the Society of Thermal Medicine (STM), European Society for Hyperthermic Oncology (ESHO) and the Asian Society of Hyperthermic Oncology (ASHO), the benefits of hyperthermia are fully realized when the tumor temperature reaches 39-43 degrees Celsius.

Heat is known to kill cancer cells, shrink tumor size, increase radiosensitivity, inhibit DNA repair, oxygenate hypoxic tumors, produce heat shock proteins, and increase disease-free survival.

Clinical Study Reveals Increased Longevity

An independent study published in the Journal of the American Medical Association (JAMA) reports on a 10 year patient follow-up to a phase III clinical study on a Soft Tissue Sarcoma Study. In addition to higher CR, the addition of hyperthermia increased the median long-term survival rate from 6.2 to 15.4 years

Infographic of Soft Tissue Sarcoma Study

hyperthermia

  • Concomitant RT and HT for primary carcinoma of the vagina

    Abstract: Concomitant radiotherapy and hyperthermia for primary carcinoma of the vagina: A cohort study

    Objective

    To evaluate the supplementary value of adding hyperthermia to radiotherapy in patients with primary vaginal cancer.

    Study design

    Cohort of 44 patients diagnosed with primary vaginal cancer between 1990 and 2002 was assessed. Survival rates and median survival of patients with primary vaginal cancer undergoing radiotherapy with and without hyperthermia were compared. Hyperthermia was solely added to radiotherapy in case of a tumor size >4 cm in diameter for FIGO stage III disease.

    Results

    The calculated overall 5-year survival of primary vaginal cancer was 63%. In comparison to histologic high grade tumors, higher survival rates for histologic low grade tumors were calculated. For FIGO stage III of disease, the addition of hyperthermia to radiotherapy for tumors >4 cm in diameter resulted similar survival rates and median survival when compared to those achieved by radiotherapy as monotherapy in tumors of <4 cm in diameter.

    Conclusions

    The addition of hyperthermia to radiotherapy might result in better survival rates in primary vaginal cancer for tumors >4 cm in diameter. The supplementary effect of hyperthermia to radiotherapy may be a feasible and beneficial approach in the treatment of vaginal cancer.

    Authors

    Aktas M, de Jong D, Nuyttens JJ, van der Zee J, Wielheesen DHM, Batman E, Burger CW, Ansink AC.

    Study Link

    Concomitant radiotherapy and hyperthermia for primary carcinoma of the vagina: A cohort study.
    European Journal of Obstetrics & Gynecology and Reproductive Biology 2007;133(1):100-4.

    {module=348}

  • Family Overview Brochure 2016

    Introduction to Pyrexar Family of Hyperthermia systems. 2 page full color.  Original available upon request for translation.

  • Pyrexar Medical brings the Thermal Therapy Message to ASTRO

    ASTRO2015Salt Lake City, UT– Pyrexar Medical, leaders in thermal therapy systems, will be exhibiting at the American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting held in San Antonio’s Henry B. Gonzalez Convention Center on October 18-20,2015.

    Pyrexar will showcase their line of superficial, interstitial and deep regional hyperthermia systems for the treatment of cancer. Clinical studies confirm that hyperthermia added to radiotherapy boosts effective dose and increases response rate without any cumulative damage to healthy tissues. Thermal Therapy is one of the most important new cancer therapies on the market and it is under-represented in the U.S.  Pyrexar will be the only manufacturer of this technology exhibiting at the show.

    It has been a very big year for the newly formed Pyrexar. Since purchasing the assets from the 30-year-old device manufacturer BSD Medical, the company has experienced phenomenal growth. This growth coincides with important clinical findings supporting the use of thermal therapy, aka hyperthermia, to treat cancer. The most recent peer review (published in Cancer Treatment Reviews) of 38 clinical studies, including cancers of the bladder, breast, cervical, esophageal, head & neck, pediatric tumors, rectal and soft tissue sarcoma, concludes that adding hyperthermia to traditional cancer treatment improves outcomes by an average of 1.8.

    “There is no better time to talk about the benefits of thermal therapy than now”, says Mark Falkowski, CEO at Pyrexar Medical.  “We are seeing an improvement in outcomes by adding a pain-free, harm-free treatment protocol to the standard of care.  Why wouldn’t you give that to a loved one if it could mean more time.” Pyrexar will be launching its #OneMoreYear campaign at the show, challenging everyone to think about what they would do if given one more year.

    You can find Pyrexar at booth 1753 at the ASTRO show October 18, 19 & 20 and later this year at RSNA Nov. 29th - Dec 4th in Chicago. To learn more about Pyrexar products and be part of the #OneMoreYear campaign, visit www.pyrexar.com.

    ABOUT PYREXAR MEDICAL:
    Pyrexar Medical is a pioneer and worldwide market leader in the development and manufacture of innovative and highly effective thermal therapy/hyperthermia treatment systems with established distribution and support networks around the world. PYREXAR HyperThermia (PYREXAR HT) treatments, proven in multiple clinical trials over the last 30 years, increase the effective dose of ionizing radiation in solid tumors up to 3X without increasing toxicity to healthy tissues.

  • What I learned at STM

    The 32nd Annual Meeting of the Society of Thermal Medicine (STM) concluded last week. The event was held at the happiest place on earth, on the edges of the Disney World resort complex in Orlando, Florida. Apropos locations as temperatures were well into the ’90s, for you thermal scientists around 35˚C, just shy of the hyperthermia therapeutic range.

    The annual event attracts clinicians and researchers with exceptional guest speakers and abstracts presented by colleagues. One of those abstracts, “Integration of Deep Hyperthermia with MR Imaging,” presented by our own Paul Turner, CTO at Pyrexar Medical. From what I witnessed, this group is made up of dedicated, passionate professionals who care deeply about treating cancer. Even our after-hours, get-togethers were filled with lively debates on the best uses of thermal therapy — many conversations requiring a Ph.D., MD, and whiteboard to sufficiently follow.

    Pyrexar was very proud to represent the BSD-500 and BSD-2000 product lines at the show, as they have become cornerstones of the thermal therapy modality. We felt very welcomed by the group and had the chance to meet some of the clinicians and researchers behind many of the successful clinical trials you can find on our website.

    We are very excited for ICHO 2016 (International Congress of Hyperthermic Oncology) currently planned for New Orleans. According to Chris Lapine, Association Manager at Allen Press, next year's conference will host not only the Society of Thermal Medicine but also ESHO – European Society of Hyperthermic Oncology and the JSTM - Japanese Society for Thermal Medicine. This combination event only happens once every four years. 2016 is going to be a great event.

    To learn more about STM visit their website www.thermaltherapy.org

Benefits of Hyperthermia in Cancer Treatment*

Effects Tumor Cell

In the delicate micro-environment of a cancer cell, heat can lead to direct cell death, shrinking tumor size for easier surgical resection.

Low Toxicity

Very low to no toxicity is often reported when administering hyperthermia. There is no known toxicity build-up from multiple treatments.

Increase Blood Flow

Increased blood flow and perfusion at the tumor site promote oxygenation, increasing radiosensitivity.

Survival Benefit

A phase III clinical study shows an increased survival benefit when hyperthermia was added to traditional therapies.

Inhibits DNA Repair

Hyperthermia, in combination with Radiotherapy, will inhibit the DNA repair cycle of radiation-damaged cancer cells.

Heat Shock Proteins

Tumor cells express heat shock proteins when exposed to hyperthermic temperatures allowing tumor-specific antigens to reach the immune system.

Our Products

 

To serve you better, this website has two viewing options.

Please make a selection before entering this site:

I am looking for products
Within the United States or Outside the United States

 
This website has restricted marketing content for visitors within the United States.